Document is current
Any future updates will be listed below
-
Authors
Hong, William
Haviland, Isabel https://orcid.org/0000-0001-6719-6368
Pestana-Knight, Elia https://orcid.org/0000-0001-9068-4167
Weisenberg, Judith L.
Demarest, Scott
Marsh, Eric D.
Olson, Heather E. https://orcid.org/0000-0002-5385-0119
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (K23 NS107646-04)
Philanthropic donation
- License Information
-
More Information
Article History
Accepted: 10 April 2022
First Online: 28 May 2022
Declarations
:
: This review was supported by the National Institute of Neurologic Disorders and Stroke (K23 NS107646-04, principal investigator HEO) and by philanthropic donation for CDD research to support WH’s fellowship in Epilepsy Genetics.
: WH and IH have no conflicts of interest that are directly relevant to the content of this article. EPK is on the scientific advisory board of Marinus Pharmaceuticals. JLW has received funding from the International Foundation for CDKL5 Research and is a site principal investigator for Marinus Pharmaceuticals. SD has consulted for Upsher-Smith, Biomarin, Neurogene, Marinus, Tysha, and Ovid Therapeutics; has received funding from the National Institutes of Health, the International Foundation for CDKL5 Research, Project 8P, and Mila's Miracle Foundation; and serves on the advisory board for the nonprofit foundations SLC6A1 Connect, Ring14 USA and FamilieSCN2A. EDM is a site principal investigator for trials for Stoke Therapeutics, GW Pharmaceuticals, Zogenix Pharmaceuticals, Acadia Pharmaceuticals, and Marinus Pharmaceuticals; was previously a consultant for Cilpa Pharmaceuticals and Stoke Therapeutics; has received research support from the National Institutes of Health, the Eagles Autism Foundation, the Penn Orphan Disease center, RettSyndrome.org, the International Foundation for CDKL5 Research, and the LouLou Foundation. HEO has consulted for Marinus Pharmaceuticals, Ovid Therapeutics, Zogenix, and Takeda Pharmaceuticals related to CDKL5 deficiency disorder; and has received clinical research funding from the International Foundation for CDKL5 Research and the LouLou Foundation/Orphan Disease Center at the University of Pennsylvania.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: WH: Conceptualization, literature search, data analysis/interpretation, manuscript draft preparation, and critical manuscript revision. IH: Literature search, data analysis/interpretation, manuscript draft preparation, and critical manuscript revision. EPK, JLW, SD, AND EDM: Data analysis/interpretation and critical manuscript revision. HEO: Conceptualization, data analysis/interpretation, manuscript draft preparation, and critical manuscript revision. All authors read and approved the final manuscript and agree to be accountable for this work.
